Core Insights - Astellas Pharma Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its strategic focuses and progress in delivering long-term impact for patients, partners, and shareholders [1][2] Company Strategy and Leadership - President and CEO Naoki Okamura will discuss Astellas' key growth drivers and commitment to disciplined execution, while Chief Research & Development Officer Tadaaki Taniguchi will emphasize advancements in transformative scientific breakthroughs for diseases with high unmet medical needs [2][3] - The company aims to turn innovative science into meaningful value for patients and drive sustainable growth, using the conference as a platform to engage with the global investment and healthcare community [3] Event Details - The presentation will take place on January 12, 2026, at 3:00 p.m. PT at the Westin St. Francis, San Francisco, with materials and a live webcast available on Astellas' Investor Relations page [8] Industry Engagement - Astellas is also a distinguished sponsor of the Biotech Showcase, further enhancing its visibility in the global life sciences community, with Chief Strategy Officer Adam Pearson participating in discussions on partnering trends that advance emerging technologies and drug development innovation [4]

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due 2032 (the "notes†) and $200 million of common stock in separate public offerings registered under the Securities Act of 1933, as amended. Arrowhead also expects to grant the underwriters of the note offering a 30-day option to purchase up to an additional $75 milli. ...

In this article, we will take a look at some of the best dividend aristocrat stocks to invest in.Dividends play a real role in equity returns. Over long stretches of time, they add up. Since 1926, dividends have made up about 31% of the S&P 500’s total return, while capital appreciation accounts for the remaining 69%. That split matters when thinking about long-term results.For most investors, total return is not just about price gains. Steady dividend income and the ability for a stock to grow over time bo ...

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive an ...

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team: ht ...

Bayer's Monsanto sued COVID-19 vaccine makers Pfizer , BioNTech and Moderna in Delaware federal court on Tuesday for allegedly misusing its messenger RNA technology in manufacturing their vaccines, a ... ...

PresentationGood morning, and welcome to the Arrowhead Pharmaceuticals' Virtual KOL event. [Operator Instructions]. As a reminder, this call is being recorded, and a replay will be available on the Arrowhead website following the event.Vincent AnzaloneHead of Investor Relations & VP Thanks so much, Wilson, and thanks, everybody, for joining us today. We are excited to talk about our first interim results from our 2 obesity candidates, ARO-INHBE and ARO-ALK7. The press release went out this morning. So I'd l ...

Robinhood’s top lawyer is joining FINRA’s Board of Governors with three other appointments, including a former chairman of the Commodity Futures Trading Commission.In addition to being Robinhood Markets’ chief legal, compliance and corporate affairs officer, Dan Gallagher is a former commissioner of the Securities and Exchange Commission. Additionally, Gallagher was rumored to be a finalist to run the agency during Trump’s second term, before withdrawing his name from consideration in late 2024. Gallagher’s ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Market Performance - European stocks closed higher, with the pan European Stoxx 600 climbing 0.58% and the U.K.'s FTSE 100 increasing by 1.18% [1] - Several European markets, including Austria, Belgium, and Spain, also recorded gains, while Iceland, Ireland, Poland, and Russia ended weak [2] Company Highlights - Next Plc shares surged 5% after upgrading profit guidance, forecasting after-tax earnings of 738.8 pence per share, driven by a more than 10% surge in sales in December [3] - In the UK market, Fresnillo climbed about 5%, while AstraZeneca, Burberry Group, and several others gained between 3% to 5% [2] - JD Sports Fashion drifted down 4.4%, and Adidas ended lower by about 4.2% following a rating downgrade by Bank of America [4] Sector Performance - In the German market, Daimler Truck Holding gained 5.3%, and Infineon moved up 5% [4] - In France, EssilorLuxottica gained more than 5%, while Edenred and Kering ended higher by about 4.3% and 4%, respectively [5] - Polish parcel locker company shares soared more than 28% after announcing an indicative buyout offer [6] Economic Indicators - The HCOB Composite PMI in Germany decreased to 51.3 in December from 52.4 in November [6] - France's inflation eased to a seven-month low in December, with the consumer price index logging an annual increase of 0.8% [7] - EU harmonized inflation slowed unexpectedly in December to 0.7% from 0.8% in November [8]